These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10394019)

  • 1. Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Aspergillus spp.
    Gurwith M
    Chemotherapy; 1999 Jun; 45 Suppl 1():34-8. PubMed ID: 10394019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Candida spp.
    Dupont B
    Chemotherapy; 1999 Jun; 45 Suppl 1():27-33. PubMed ID: 10394018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of amphotericin B colloidal dispersion. An overview.
    Herbrecht R; Letscher V; Andres E; Cavalier A
    Chemotherapy; 1999 Jun; 45 Suppl 1():67-76. PubMed ID: 10394023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin B colloidal dispersion.
    Patel R
    Expert Opin Pharmacother; 2000 Mar; 1(3):475-88. PubMed ID: 11249532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients.
    Noskin G; Pietrelli L; Gurwith M; Bowden R
    Bone Marrow Transplant; 1999 Apr; 23(7):697-703. PubMed ID: 10218847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant.
    Bowden RA; Cays M; Gooley T; Mamelok RD; van Burik JA
    J Infect Dis; 1996 May; 173(5):1208-15. PubMed ID: 8627074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
    Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
    Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal sparing by amphotericin B colloidal dispersion: clinical experience in 572 patients.
    Gurwith M; Mamelok R; Pietrelli L; Du Mond C
    Chemotherapy; 1999 Jun; 45 Suppl 1():39-47. PubMed ID: 10394020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
    White MH; Anaissie EJ; Kusne S; Wingard JR; Hiemenz JW; Cantor A; Gurwith M; Du Mond C; Mamelok RD; Bowden RA
    Clin Infect Dis; 1997 Apr; 24(4):635-42. PubMed ID: 9145737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B colloidal dispersion. Pre-clinical review.
    Working PK
    Chemotherapy; 1999 Jun; 45 Suppl 1():15-26. PubMed ID: 10394017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion.
    Herbrecht R; Letscher-Bru V; Bowden RA; Kusne S; Anaissie EJ; Graybill JR; Noskin GA; Oppenheim ; Andrès E; Pietrelli LA
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):460-6. PubMed ID: 11561801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of amphotericin B colloidal dispersion.
    Herbrecht R
    Eur J Clin Microbiol Infect Dis; 1997 Jan; 16(1):74-80. PubMed ID: 9063677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses.
    Oppenheim BA; Herbrecht R; Kusne S
    Clin Infect Dis; 1995 Nov; 21(5):1145-53. PubMed ID: 8589134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis.
    Allende MC; Lee JW; Francis P; Garrett K; Dollenberg H; Berenguer J; Lyman CA; Pizzo PA; Walsh TJ
    Antimicrob Agents Chemother; 1994 Mar; 38(3):518-22. PubMed ID: 8203848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
    Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotericin B--not so terrible.
    Bishara J; Weinberger M; Lin AY; Pitlik S
    Ann Pharmacother; 2001 Mar; 35(3):308-10. PubMed ID: 11261528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.
    Amantea MA; Bowden RA; Forrest A; Working PK; Newman MS; Mamelok RD
    Chemotherapy; 1999 Jun; 45 Suppl 1():48-53. PubMed ID: 10394021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
    Walsh TJ; Goodman JL; Pappas P; Bekersky I; Buell DN; Roden M; Barrett J; Anaissie EJ
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3487-96. PubMed ID: 11709329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.